PD-L1基因改变定义具有T细胞炎症表型的弥漫大B细胞淋巴瘤亚群
该研究采用荧光原位杂交在105例弥漫大B细胞淋巴瘤(DLBCL)中检测PD-L1基因改变,发现27%存在改变,且在非生发中心型中富集并伴强PD-L1蛋白表达。PD-L1改变型DLBCL富含克隆性限制性T细胞浸润、常下调HLA表达,并富集负性T细胞调控与NF-κB通路基因上调及抗原呈递/共刺激基因突变;此类患者一线化疗免疫治疗后无进展生存较差,但在复发/难治背景下与抗PD-1治疗反应相关。
要点
- 105例DLBCL中27%存在PD-L1基因改变,非生发中心型富集并伴强PD-L1蛋白表达。
- PD-L1改变型DLBCL富含克隆性限制性T细胞浸润并常下调HLA表达。
- PD-L1改变患者一线化疗免疫治疗后无进展生存较差,但复发/难治时与抗PD-1治疗反应相关。
核心结论
- PD-L1基因改变定义了一个独特的DLBCL生物学亚群,其内源性抗淋巴瘤免疫反应已被激活,并与PD-1阻断治疗反应性相关。
研究设计与样本
- 研究采用荧光原位杂交在105例DLBCL中检测PD-L1基因改变,并对PD-L1改变型DLBCL进行RNA测序和全外显子测序,部分结果在大型外部数据集中验证。
主要发现
- 105例DLBCL中27%存在PD-L1基因改变,且在非生发中心DLBCL中高度富集并表现出强PD-L1蛋白表达。
- PD-L1改变型DLBCL被克隆性限制性T细胞重度浸润,并频繁下调人白细胞抗原表达。
- RNA测序显示PD-L1改变型DLBCL中参与负性T细胞调控和NF-κB通路激活的基因上调。
- 全外显子测序发现PD-L1改变型DLBCL频繁突变于参与抗原呈递和T细胞共刺激的基因。
- PD-L1改变的DLBCL患者一线化疗免疫治疗后无进展生存较差,但在复发/难治背景下PD-L1改变与抗PD-1治疗反应相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Programmed death-ligand 1 (PD-L1) expression on malignant cells is a dominant immune escape mechanism across a variety of human cancers. A unique genetic mechanism underlying PD-L1 upregulation has been uncovered in classical Hodgkin lymphoma (cHL), in which copy gains of the chromosomal region (9p24.1) containing the programmed death-1 (PD-1) ligands PD-L1 and PD-L2 are recurrently observed. While chromosome 9p24.1 copy-number alterations are ubiquitous in cHL, they also occur in diffuse large B-cell lymphoma (DLBCL), albeit with a lower incidence. Here, fluorescence in situ hybridization was used to identify DLBCLs harboring PD-L1 gene alterations, thereby enabling a characterization of the immunogenomic landscape of these lymphomas. Among 105 DLBCL cases analyzed, PD-L1 alterations were identified in 27%. PD-L1 alterations were highly enriched among non-germinal center DLBCLs and exhibited robust PD-L1 protein expression. These lymphomas were heavily infiltrated by clonally restricted T cells and frequently downregulated human leukocyte antigen expression. RNA sequencing of PD-L1-altered DLBCLs revealed upregulation of genes involved in negative T-cell regulation and NF-κB pathway activation, while whole-exome sequencing identified frequent mutations in genes involved in antigen presentation and T-cell costimulation. Many of these findings were validated in a large external data set. Interestingly, DLBCL patients with PD-L1 alterations had inferior progression-free survival following front-line chemoimmunotherapy; however, in the relapsed/refractory setting, PD-L1 alterations were associated with response to anti-PD-1 therapy. Collectively, our results indicate that PD-L1 alterations identify a unique biological subset of DLBCL in which an endogenous antilymphoma immune response has been activated, and that is associated with responsiveness to PD-1 blockade therapy.
引用
- Godfrey J, Tumuluru S, Bao R, et al. PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. Blood. 2019. PMID: 30910787. doi:10.1182/blood-2018-10-879015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。